TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06228326: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Sponsor: Krystal Biotech, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 250 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$12,173,700

Rescue Site Savings

+$8,050,350

Unlock Full NCT06228326 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06228326 Rescue Dossier →